Bank of America Corp DE boosted its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 148.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,946,861 shares of the company's stock after purchasing an additional 1,760,610 shares during the period. Bank of America Corp DE owned about 1.06% of Sana Biotechnology worth $8,487,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the company. Royal Bank of Canada raised its stake in shares of Sana Biotechnology by 76.8% in the first quarter. Royal Bank of Canada now owns 12,285 shares of the company's stock valued at $35,000 after acquiring an additional 5,338 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Sana Biotechnology in the 3rd quarter valued at $36,000. Rockefeller Capital Management L.P. raised its position in Sana Biotechnology by 74.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock valued at $39,000 after purchasing an additional 4,088 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Sana Biotechnology in the third quarter worth $39,000. Finally, LRI Investments LLC acquired a new position in Sana Biotechnology in the fourth quarter worth $41,000. 88.23% of the stock is owned by institutional investors.
Sana Biotechnology Price Performance
Shares of NASDAQ SANA opened at $3.78 on Tuesday. The company's 50 day simple moving average is $3.49 and its 200 day simple moving average is $3.41. Sana Biotechnology, Inc. has a fifty-two week low of $2.61 and a fifty-two week high of $6.55. The firm has a market capitalization of $1.13 billion, a P/E ratio of -4.97 and a beta of 2.16.
Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. Sell-side analysts expect that Sana Biotechnology, Inc. will post -0.72 EPS for the current fiscal year.
Analyst Ratings Changes
SANA has been the subject of a number of research analyst reports. Rodman & Renshaw started coverage on Sana Biotechnology in a report on Monday, May 11th. They issued a "buy" rating and a $16.00 price target for the company. Weiss Ratings raised shares of Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, July 23rd. Wall Street Zen cut shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a research report on Monday, July 20th. Finally, Bank of America dropped their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating for the company in a research note on Friday, August 14th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $9.33.
Check Out Our Latest Analysis on Sana Biotechnology
Sana Biotechnology Company Profile
(
Free Report)
Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.
The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.
Read More
Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
